Startups
Naobios
Edit

Naobios

https://www.naobios.com/
Last activity: 11.12.2023
Active
Categories: BioTechDevelopmentManufacturingProductResearchService
Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.
Followers
1.97K
Mentions
3

Overview

Location
France, Pays de la Loire, Saint-Herblain
Employees
11-50
Total raised
$1.87M

Funding Rounds 1

DateSeriesAmountInvestors
Sign up to seeSign up to seeSign up to seeSign up to see

Mentions in press and media 3

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Dec 11, 2023Naobios awarded €1.7M grant for vaccine development by Bill & Melinda Gates foundationToday Naobios, a contract development and manufacturing company that provides bioprocess development and production of clinical batches of virus-based products, announced that it has received a €1.7M grant from the Bill & Melinda Gates ...
Jul 9, 2023Manufacturing Marvels: Unveiling 15 Innovative Startups Revolutionizing the Industry in FranceTable of Contents show 1 Exploring the Cutting-Edge Manufacturing Startups Redefining the Landscape of French Innovation 1.1 BlueNav: Empowering the Future of Electric Motors 1.2 auum: Reinventing Hygiene Practices 1.3 K-Motors: Revolut...

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Naobios

How much funding has Naobios raised?

Naobios has raised $1.87M in total across 1 funding round.

What has the press written about Naobios?

Parsers VC has collected 3 articles mentioning Naobios, among them “Naobios awarded €1.7M grant for vaccine development by Bill & Melinda Gates foundation” (Dec 11, 2023) and “Manufacturing Marvels: Unveiling 15 Innovative Startups Revolutionizing the Industry in France” (Jul 9, 2023).

Is Naobios still active?

Yes, Naobios is active; its latest activity on Parsers VC dates from Dec 11, 2023.